Press Releases

Month Year

Month Year

May 17, 2022

Insmed Presents New Data Across Three Pillars at American Thoracic Society 2022 International Conference

Read more
May 17, 2022

Insmed To Present at the H.C. Wainwright Annual Global Life Sciences Conference

Read more
May 6, 2022

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
May 5, 2022

Insmed Reports First Quarter 2022 Financial Results and Provides Business Update

Read more
Apr 21, 2022

Insmed to Host First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022

Read more
Apr 7, 2022

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
Mar 28, 2022

Insmed to Showcase New Data Across Three Pillars at the American Thoracic Society 2022 International Conference

Read more
Mar 4, 2022

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
Mar 3, 2022

Insmed To Present at the Cowen 42nd Annual Health Care Conference

Read more
Feb 17, 2022

Insmed Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business and Pipeline Update

--ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $56.1 Million for the Fourth Quarter and $188.5 Million for the Full Year 2021; Anticipate at Least 30% Year Over Year Annual Growth for 2022--

Read more

Show per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your email alerts.

Investor Presentation

View the latest Insmed Investor Presentation